

Bod to fast track Phase I clinical trials of cannabis extract and delivery method

Highlights:

- **Bod has engaged with significant counterparties, Linnea, iX Biopharma and ex head of clinical trials for Sirtex Medical in developing its clinical trial program**
- **Extensive literature review completed – ‘trial ready’ deliverable method underway with formulation and dosages determined**
- **Significant reduction in estimated study timeframe reduced from 10 months to 3 months**
- **Improved Phase I study design to provide more data with lower costs**
- **Trial designed assesses the safety, tolerability and pharmacokinetics of Bod’s unique cannabis extract and sublingual wafer delivery method**
- **Trials set to commence first half 2018**

Sydney, Australia – 11 January 2018 – Developer and distributor of natural, evidence-based cosmetics and health products Bod Australia Limited (“**Bod**” or the “**Company**”) (ASX: BDA) is pleased to report it has made significant progress towards a Phase I clinical trial of its novel pharmaceutical-grade medicinal cannabis extract and delivery system.

Bod has engaged with highly credible counter parties to source and develop its clinical trial program as follows:

- Cannabis extract – globally unique, phytocomplex cannabis extract, sourced from Swiss company Linnea owned by Schwabe and Ipsen (EPA:IPN – Market Cap €8.9Bn)
- Delivery method – exclusively sourced from innovative late-stage specialty pharmaceutical company iX Biopharma Ltd (SGX:42C – Market Cap ~SGD\$120m)
- Clinical trial program – formulation, design and dosage determined by ex-head of global clinical trials of Sirtex Medical Ltd (ASX:SRX – Market Cap ~A\$880m)

Bod Australia has now completed an extensive literature review, and has also determined the unique formulation and dosage requirement to be used in the Phase I trial. As a result of the literature review, the Company has identified opportunities to improve its trials’ clinical design.

This improved study design will reduce the cost of conducting the Phase I trial by reducing sample size, without compromising results. It will also significantly shorten the length of the trial to 3 months, rather than the 10-month timeframe originally estimated.

Other improvements to the study include access to more data for future studies and formulations, including a comparison to the only other approved medicinal cannabis product that is currently being trialled in the Australian market.

The Phase I trial will take place in the first half of 2018 and will assess the safety, tolerability and pharmacokinetics of Bod’s unique sublingual formulation of cannabis, utilising Linnea’s phytocomplex extract in oil and powder form and iX Biopharma’s patented wafer delivery system.

Upon the successful completion of the Phase I trial, Bod will investigate opportunities for its Phase II study, with initial target indications focussing on post chemotherapy-induced nausea and vomiting, epilepsy and multiple sclerosis.

The intention of the Phase II trial is to provide research into the efficacy of the therapeutic effects of the Company's proposed cannabis based product, with the ultimate aim, subject to any regulatory requirements, of becoming the third product in the Company's evidenced based natural medicines portfolio alongside Flexofytol and Pinpoint.

Bod Australia CEO Jo Patterson said: "The improvements we have implemented to our Phase I trial will drastically reduce the time our study takes from at least seven months to three. Our design enhancements deliver a significantly reduced time to market and much better cost savings, along with a higher quality of data.

"Following the Company's agreement with Singapore based iX Biopharma Limited, we are pleased to report that development of a 'trial ready' deliverable method is underway at its Australian facilities and is progressing well.

"We look forward to updating shareholders on additional progress regarding Phase I Clinical Trials and other developments as they become available."

For more information: bodaustralia.com

- ENDS -

About Bod Australia

Bod Australia Limited operates two integrated business units. The Company is a developer and distributor of cosmetics and natural medicines, focused on all natural, evidence based products. Bod has developed a significant distribution footprint in the Australian market with access to over 800 pharmacies and is also targeting Asian markets through key daigou relationships. Bod Australia is also building a sustainable, multi-faceted cannabis business through a supply and collaboration agreement with Swiss botanical extracts manufacturer, Linnea Natural Pharma Solutions. The Company aims to develop a range of over the counter and therapeutic products based on GMP-certified cannabis extracts.

For more information please contact:

Jo Patterson
Bod Australia
+61 2 9199 5018

Henry Jordan – Six Degrees Investor Relations
Henry.jordan@sdir.com.au
+61 431 271 538